<DOC>
	<DOCNO>NCT02200822</DOCNO>
	<brief_summary>The primary objective study demonstrate patient recuperated/normalized leave ventricular function , define ejection fraction ( EF ) ≥ 50 % , implantation cardiac resynchronization therapy , device treatment sufficient neurohumoral blocker therapy safely withdrawn</brief_summary>
	<brief_title>Systematic Withdrawal Neurohumoral Blocker Therapy Optimally Responding CRT Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>≥18 year CRT implantation base class I recommendations ESC ( European society CArdiology ) guideline : Left bundle branch block ( LBBB ) QRS duration &gt; 150 m leave ventricular ejection fraction ( LVEF ) ≤35 % remain NYHA functional class II , III ambulatory IV despite adequate medical treatment LBBB QRS duration 120150 m LVEF ≤ 35 % remain NYHA functional class II , III ambulatory IV despite adequate medical treatment At moment inclusion : ≥ 6 month implantation At moment inclusion : normalised LVEF ( ≥ 50 % ) , LVIDD/BSA ( leave ventricular internal diastolic diameter index body surface area ) ≤3.2 cm/m² ( woman ) en ≤3.1 cm/m² ( men ) LVDV/BSA ( leave ventricular diastolic volume index body surface area ) ≤75 ml/m² ( woman ) ≤75 ml/m² ( men ) euvolemic clinical state function NYHA class I contraindication withdrawal ACEI/ARB diabetic nephropathy proteinuria &gt; 1g / 24 h severe ventricular arrythmia ( sustain VT ventricular fibrillation ) occur time LV function normalize ischemic cardiomyopathy evidence scarring ( scar MRI severe hypokinesia/akinesia &gt; 1 LV wall segment echocardiography ) know severe coronary atherosclerosis ( stenosis ≥ 80 % )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>neurohumoral blocker therapy</keyword>
	<keyword>renin-angiotensin-aldosterone system ( RAAS )</keyword>
	<keyword>RAAS-blocker</keyword>
	<keyword>beta blocker</keyword>
	<keyword>spironolactone</keyword>
	<keyword>angiotensin convert enzyme inhibitor ( ACE-I )</keyword>
	<keyword>angiotensin receptor blocker ( ARB )</keyword>
	<keyword>cardiac resynchronization therapy ( CRT )</keyword>
	<keyword>heart failure</keyword>
	<keyword>dyssynchrony</keyword>
	<keyword>leave bundle branch block</keyword>
</DOC>